The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–16. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Won K-A, Spruck C. Triple‑negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–1261. doi:10.3892/ijo.2020.5135.
   PubMed Web of Science ®Google Scholar
• Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 2022;17(1):181–204. doi:10.1146/annurev-pathol-042420-093238.
   PubMedGoogle Scholar
• Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0.
   PubMed Web of Science ®Google Scholar
• Bragulla HH, Homberger DG. Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. J Anat. 2009;214(4):516–559. doi:10.1111/j.1469-7580.2009.01066.x.
   PubMed Web of Science ®Google Scholar
• Shavandi A, Silva TH, Bekhit AA, Bekhit A-D. Keratin: dissolution, extraction and biomedical application. Biomater Sci. 2017;5(9):1699–1735. doi:10.1039/C7BM00411G.
   PubMed Web of Science ®Google Scholar
• Yoon S, Leube RE, Malliri A, Caswell P, Ballestrem C, Hurlstone A. Keratin intermediate filaments: intermediaries of epithelial cell migration. Essays Biochem. 2019;63(5):521–533. doi:10.1042/EBC20190017.
   PubMed Web of Science ®Google Scholar
• Polari L, Alam CM, Nyström JH, Heikkilä T, Tayyab M, Baghestani S, Toivola DM. Keratin intermediate filaments in the colon: guardians of epithelial homeostasis. Int J Biochem Cell Biol. 2020;129:105878. doi:10.1016/j.biocel.2020.105878.
   PubMed Web of Science ®Google Scholar
• Zhu R-J, Zhou J, Liang P-Q, Xiang X-X, Ran J, Xie T-A, Guo X-G. Accuracy of cytokeratin 19 fragment in the diagnosis of bladder cancer. Biomark Med. 2022;16(3):197–216. doi:10.2217/bmm-2021-0754.
   PubMed Web of Science ®Google Scholar
• Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011;30(2):127–138. doi:10.1038/onc.2010.456.
   PubMed Web of Science ®Google Scholar
• Sharma P, Alsharif S, Fallatah A, Chung BM. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells. 2019;8(5):497. doi:10.3390/cells8050497.
   PubMed Web of Science ®Google Scholar
• Ogunnigbagbe O, Bunick CG, Kaur K. Keratin 1 as a cell-surface receptor in cancer. Biochim Biophys Acta Rev Cancer. 2022;1877(1):188664. doi:10.1016/j.bbcan.2021.188664.
   PubMed Web of Science ®Google Scholar
• Verma A, Singh A, Singh MP, Nengroo MA, Saini KK, Satrusal SR, Khan MA, Chaturvedi P, Sinha A, Meena S, et al. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nat Commun. 2022;13(1):7344. doi:10.1038/s41467-022-35059-x.
   PubMed Web of Science ®Google Scholar
• Ziaei E, De Paiva IM, Yao S-J, Sarrami N, Mehinrad P, Lai J, Lavasanifar A, Kaur K. Peptide–drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice. Mol Pharmaceutics. 2023;20(7):3570–3577. doi:10.1021/acs.molpharmaceut.3c00189.
   PubMed Web of Science ®Google Scholar
• Fallatah A, Anastasakis DG, Manzourolajdad A, Sharma P, Wang X, Jacob A, Alsharif S, Elgerbi A, Coulombe PA, Hafner M, et al. Keratin 19 binds and regulates cytoplasmic HNRNPK mRNA targets in triple-negative breast cancer. BMC Mol And Cell Biol. 2023;24(1):26. doi:10.1186/s12860-023-00488-z.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. 2019. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 79(18):4557–4566. doi: 10.1158/0008-5472.CAN-18-3962.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Y-X F. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1.
   PubMed Web of Science ®Google Scholar
• So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: e merging treatment options. Pharmacol Ther. 2022;237:108253. doi:10.1016/j.pharmthera.2022.108253.
   PubMed Web of Science ®Google Scholar
• Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol. 2021;226:108707. doi:10.1016/j.clim.2021.108707.
   PubMed Web of Science ®Google Scholar
• Deng X-X, Jiao Y-N, Hao H-F, Xue D, Bai C-C, Han S-Y. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10/STAT3/PD-L1 signaling pathways. J Ethnopharmacol. 2021;274:113978. doi:10.1016/j.jep.2021.113978.
   PubMed Web of Science ®Google Scholar
• Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng S-Y, Chen C, Chen G, Li Y, Feng H. KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer. Adv Sci (Weinheim, Baden-Wurttemberg, Ger). 2021;8(20):e2100014. doi:10.1002/advs.202100014.
   PubMedGoogle Scholar
• Li Y, Han X, Lin Z, Wang C, Fu Z, Sun Q, Li C. G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression. Cell Mol Life Sci. 2023;80(6):165. doi: 10.1007/s00018-023-04810-y.
   PubMed Web of Science ®Google Scholar
• Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022;12:919072. doi:10.3389/fonc.2022.919072.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019.
   PubMed Web of Science ®Google Scholar
• Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–367. doi:10.1038/s41416-020-01048-4.
   PubMed Web of Science ®Google Scholar
• Katz H, Alsharedi M. Immunotherapy in triple-negative breast cancer. Med Oncol. 2017;35(1):13. doi:10.1007/s12032-017-1071-6.
   PubMed Web of Science ®Google Scholar
• Feng Y, Lee J, Yang L, Hilton MB, Morris K, Seaman S, Edupuganti VVSR, Hsu K-S, Dower C, Yu G, et al. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability. Cell Rep. 2023;42(12):113503. doi:10.1016/j.celrep.2023.113503.
   PubMed Web of Science ®Google Scholar
• Merhi M, Ahmad F, Taib N, Inchakalody V, Uddin S, Shablak A, Dermime S. The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update. Semin Cancer Biol. 2023;89:1–17. doi:10.1016/j.semcancer.2023.01.001.
   PubMedGoogle Scholar
• Liu L, Mo M, Chen X, Chao D, Zhang Y, Chen X, Wang Y, Zhang N, He N, Yuan X, et al. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. J Exp Clin Cancer Res. 2023;42(1):85. doi:10.1186/s13046-023-02647-8.
   PubMed Web of Science ®Google Scholar
• Redler S, Pasternack SM, Wolf S, Stienen D, Wenzel J, Nöthen MM, Betz RC. A novel KRT86 mutation in a Turkish family with monilethrix, and identification of maternal mosaicism. Clin Exp Dermatol. 2015;40(7):781–785. doi: 10.1111/ced.12631.
   PubMed Web of Science ®Google Scholar
• Sha Z, Lai R, Zhang X, Zhao Y, Wu J, Geng C, Guo Z. A polymorphism at the microRNA binding site in the 3’ untranslated region of KRT81 is associated with breast cancer. DNA Cell Biol. 2020;39(10):1886–1894.
   PubMed Web of Science ®Google Scholar
• Nanashima N, Horie K, Yamada T, Shimizu T, Tsuchida S. Hair keratin KRT81 is expressed in normal and breast cancer cells and contributes to their invasiveness. Oncol Rep. 2017;37(5):2964–2970. doi:10.3892/or.2017.5564.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang H-L, Li Z-L, Du T, Chen Y-H, Wang Y, Ni H-H, Zhang K-M, Mai J, Hu B-X, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021;12(1):2672. doi: 10.1038/s41467-021-22618-x.
   PubMed Web of Science ®Google Scholar
• Dominguez C, McCampbell KK, David JM, Palena C. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-neg ative breast cancer. JCI Insight. 2017;2(21).
   PubMed Web of Science ®Google Scholar
• Zhang K, Liang Y, Zhang W, Zeng N, Tang S, Tian R. KRT81 knockdown inhibits malignant progression of melanoma through regulating interleukin-8. DNA Cell Biol. 2021;40(10):1290–1297.
   PubMed Web of Science ®Google Scholar
• Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18(4):479–489. doi:10.6004/jnccn.2020.7554.
   PubMed Web of Science ®Google Scholar
• Stark R, Grzelak M, Hadfield J. RNA sequencing: the teenage years. Nat Rev Genet. 2019;20(11):631–656. doi:10.1038/s41576-019-0150-2.
   PubMed Web of Science ®Google Scholar
• Gul S, Pang J, Yuan H, Chen Y, Yu Q, Wang H, Tang W. Stemness signature and targeted therapeutic drugs identification for triple negative breast cancer. Sci Data. 2023;10(1):815. doi:10.1038/s41597-023-02709-8.
   PubMed Web of Science ®Google Scholar
• Ran X, Tong L, Chenghao W, Qi L, Bo P, Jiaying Z, Jun W, Linyou Z. Single-cell data analysis of malignant epithelial cell heterogeneity in lung adenocarcinoma for patient classification and prognosis prediction. Heliyon. 2023;9(9):e20164. doi:10.1016/j.heliyon.2023.e20164.
   PubMed Web of Science ®Google Scholar
• Wang X, Miao J, Wang S, Shen R, Zhang S, Tian Y, Li M, Zhu D, Yao A, Bao W, et al. Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells. Mol Cancer. 2022;21(1):133. doi: 10.1186/s12943-022-01596-8.
   PubMed Web of Science ®Google Scholar